---
schema_version: "secwatch.filing_event.v1"
accession: "0001746473-26-000115"
form_type: "8-K"
ticker: "PLRX"
cik: "0001746473"
company_name: "PLIANT THERAPEUTICS, INC."
filed_at: "2026-08-11T20:10:31+00:00"
generated_at: "2026-08-11T20:12:45.692876+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Pliant Therapeutics Q2 2026 net loss narrows to $22.4M; FORTIFY enrollment ahead of schedule

## Summary
- Q2 2026 net loss $22.4M vs $43.3M prior-year; R&D spend $16.7M vs $32.2M, G&A $7.1M vs $13.4M on bexotegrast termination and headcount cuts.
- Cash, equivalents and short-term investments of $159.6M at June 30, 2026; expected to fund operations into second half of 2028.
- FORTIFY Phase 1b trial of PLN-101095 enrolling ahead of schedule; up to 102 patients across 3 cohorts; interim data expected 2027.
- Appointed Flavia Borellini, Ph.D. and Robert Iannone, M.D. (Jazz Pharmaceuticals EVP R&D/CMO) to Board of Directors.
- AACR data: PLN-101095 monotherapy raised IFN-γ, CXCL9 and granzyme-B only in responders, signaling T-cell reactivation.

## SEC filing metadata
- accession: 0001746473-26-000115
- form_type: 8-K
- ticker: PLRX
- cik: 0001746473
- company_name: PLIANT THERAPEUTICS, INC.
- filed_at: 2026-08-11T20:10:31+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1746473/000174647326000115/0001746473-26-000115-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1746473/000174647326000115/plrx-20260811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001746473-26-000115
- JSON: https://secwatch.observer/filing/0001746473-26-000115.json
- Plain text: https://secwatch.observer/filing/0001746473-26-000115.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.